-
Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish a RMB 5 billion (USD 695 million) fund in collaboration with seven other investors, with Shenzhen FOF expected to contribute 50% of the total funding. The initiative aims to enhance resource sharing and cooperation between…
-
Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment
•
Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering a world-class business environment in the medical administration sector. The initiatives focus on enhancing service levels, advancing benchmarking reforms, and optimizing regulatory supervision. Key measures include:
-
Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial
•
Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The study successfully met its primary endpoint, demonstrating an improvement in overall survival (OS)…
-
MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl Bio, a synthetic biology company, to leverage Pearl’s genomically recoded organisms (GROs) platform. This platform is designed for the discovery and development of biologic molecules that incorporate non-standard amino acids, enabling the targeting of previously…
-
MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer
•
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ: IDYA), a US-based biotechnology company, to clinically develop the combination of MSD’s top-selling anti-PD-1 therapy Keytruda (pembrolizumab) with IDEAYA’s potential first-in-class poly (ADP-ribose) glycohydrolase (PARG) inhibitor IDE161. The collaboration focuses on treating microsatellite instability-high (MSI-high)…
-
Innovent Biologics Allegedly Closes US Research Facility, Shifts Focus to China
•
Innovent Biologics (HKG: 1801), a China-based biotech firm, has reportedly closed down a research team at its US headquarters in Rockville, Maryland, according to BioSpace. The wet lab facility is anticipated to be fully shut down in the near future. While Innovent has not issued an official statement regarding these…
-
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
•
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership with Minaris Regenerative Medicine, a cell and gene therapy (CGT) Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Japan-headquartered Showa Denko Materials Co., Ltd. This collaboration aims to integrate VectorBuilder’s superior R&D and…
-
Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors
•
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received approval from the National Medical Products Administration to conduct a Phase Ib/II study for its antibody drug conjugate (ADC) BAT8008 in combination with BAT1308 for the treatment of advanced solid tumors. BAT8008 is an innovative ADC that consists of…
